


# Myeloid / Lymphoid Neoplasm with PDGFRA Rearrangement Presenting as T-LBL Rodrigo Santoscoy-Valencia MD, Luiz P. De Lima Guido MD, Jennifer Chapman MD, Daniel P. Cassidy MD University of Miami / Jackson Memorial Hospital


# Introduction

- Myeloid/lymphoid neoplasms with eosinophilia (M/LNs-Eo) and rearrangements of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2 genetic variants constitute a rare but well-defined category of hematologic malignancies recognized by the WHO classification.
- Myeloid/lymphoid neoplasms with PDGFRA rearrangements are the most frequent of these disorders and is most common in middle aged males. These neoplasms are extremely rare in the pediatric population.
- The majority of cases are characterized by cytogenetically cryptic deletion of 4q12, resulting in formation of the FIP1L1::PDGFRA fusion gene, although other partner genes have been described.


## Case Presentation

- 72 year old male with history of DLBCL diagnosed in Sept. 2016 and treated with R-CHOP + radiotherapy. In remission since March 2017.
- May 2021 follow-up showed enlarged submandibular lymph node without B symptoms.





## Lymph Node, Bone Marrow and Peripheral Smear



## Discussion

- We present a case of M/LNs-Eo with PDGFRA rearrangement, which first presented as T-LBL with no marrow involvement.
- The original diagnosis of T-LBL was made because at that time there was no PB eosinophilia and molecular testing was not performed on the samples.
- This demonstrates that M/LNs-Eo can present solely as T-LBL with seemingly normal marrow and PB findings.
- When presented with eosinophilia, clonal processes to consider are CML, CMML, CHES, MDS, TCL, CHL, systemic mastocytosis, and M/LNs-Eo.
- While clonal eosinophilia in association with T-NHL is rare, it highlights the need to expand the differential diagnosis and consider these other potential underlying clonal conditions.
- NGS on our case was done on the relapse BMBx as part of a broader screen for myeloid neoplasms and ultimately revealed the fusion.
- This case highlights the importance of using comprehensive molecular testing panels for an early and accurate diagnosis, but also emphasizes the importance of thoroughly investigating eosinophilia, even in a post-therapy setting, to ensure the correct diagnosis is made.

## References

- Sanam Loghavi, Mrinal Patnaik, Eric Padron, et al. Myeloid/lymphoid neoplasm with PDGFRA rearrangement In: WHO Classification of Tumours Editorial Board. Haematolymphoid tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2024 [cited 2025 01 05]. (WHO classification of tumours series, 5th ed.; vol. 11). Available from: <u>https://tumourclassification.iarc.who.int/chapters/63</u>.
- 2. Pozdnyakova O, Orazi A, Kelemen K, King R, Reichard KK, Craig FE, Quintanilla-Martinez L, Rimsza L, George TI, Horny HP, Wang SA. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2. Am J Clin Pathol. 2021 Feb 4;155(2):160-178. doi: 10.1093/ajcp/aqaa208. PMID: 33367495.